Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 60 |
| Active Pipeline (Recruiting Now) | 36 (24) |
| Completed vs Stopped Early | 10 / 14 (23.3%) |
| Median Closed Actual Enrollment | 40 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle, WA | 56 |
| Moffitt Cancer Center | Tampa, FL | 7 |
| City of Hope National Medical Center | Duarte, CA | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05952804 | IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase II | RECRUITING |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Ste | Phase II | ACTIVE NOT RECRUITING |
| NCT04965597 | Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 19 | Phase II | COMPLETED |
| NCT03870750 | Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail | Phase II/III | TERMINATED |
| NCT04706507 | Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis | Phase III | TERMINATED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fred Hutchinson / UW Medicine across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Fred Hutchinson Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.